286 Appendices 34. Goldstraw P. Editorial Rx. In: The IASLC Staging Manual in Thoracic Oncology. Orange Park; 2009:37-38. 35. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia. 2009;15(1):4-9. 36. Curtin F, Schulz P. Multiple correlations and Bonferroni’s correction. Biol Psychiatry. 1998;44(8):775-777. doi:10.1016/s0006-3223(98)00043-2 37. Thunnissen FBJM, Schuurbiers OCJ, Den Bakker MA. A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology. 2006;48(7):779-786. doi:10.1111/j.1365-2559.2006.02386.x 38. Fischer S, Darling G, Pierre AF, et al. Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg. 2008;33(6):1129-1134. doi:10.1016/j.ejcts.2008.03.008 39. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20(2):231-238. doi:10.1093/annonc/mdn622 40. Harrison L, Blackwell K. Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist. 2004;9(S5):31-40. doi:10.1634/ theoncologist.9-90005-31 41. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther. 2002;1(5):453-458. doi:10.4161/cbt.1.5.157 42. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-1530. doi:10.1002/cncr.11660 43. Blaauwgeers JL, Kappers I, Klomp HM, et al. Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Arch. 2013;462(5):547-556. doi:10.1007/s00428-013-1404-6 44. Song Z, Yu X, Zhang Y. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer. 2016;99:166171. doi:10.1016/j.lungcan.2016.07.013 45. Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol. 2020;15(5):709-740. doi:10.1016/j.jtho.2020.01.005 46. Fleege, JC, Diest, PJ van, Baak J. Reliability of quantitative pathological assessments, standards, and quality control measurement of nuclei. In: Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. ; 1991:155-167. 47. Jakobsen JN, Sørensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79(1):1-7. doi:10.1016/j.lungcan.2012.10.008 48. Wei D ming, Chen W jie, Meng R mei, et al. Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: An updated systematic review and meta-analysis with 108 studies and 14,732 patients. Respir Res. 2018;19(1):1-19. doi:10.1186/s12931-018-0843-7 49. Butter R, Hart’t NA, Hooijer GKJ, et al. Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. J Clin Pathol. Published online 2019:423-430. doi:10.1136/jclinpath-2019-205993 50. Thunnissen E, Kerr KM, Dafni U, et al. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungs. Mod Pathol. 2020;33(5):792-801. doi:10.1038/s41379019-0383-9
RkJQdWJsaXNoZXIy MTk4NDMw